MX392760B - Modificacion dirigida al sitio del factor viii. - Google Patents

Modificacion dirigida al sitio del factor viii.

Info

Publication number
MX392760B
MX392760B MX2017007144A MX2017007144A MX392760B MX 392760 B MX392760 B MX 392760B MX 2017007144 A MX2017007144 A MX 2017007144A MX 2017007144 A MX2017007144 A MX 2017007144A MX 392760 B MX392760 B MX 392760B
Authority
MX
Mexico
Prior art keywords
factor viii
modification directed
site
viii site
modification
Prior art date
Application number
MX2017007144A
Other languages
English (en)
Spanish (es)
Inventor
Baisong Mei
Clark Q Pan
Deqian Wang
Hendri Tjandra
Jianmin Chen
John E Murphy
Jonathan S Strauss
Liang Tang
Thomas Barnett
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX392760(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX392760B publication Critical patent/MX392760B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
MX2017007144A 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii. MX392760B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (1)

Publication Number Publication Date
MX392760B true MX392760B (es) 2025-03-24

Family

ID=36337298

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007144A MX392760B (es) 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii.
MX2007005466A MX2007005466A (es) 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii.
MX2014005051A MX350293B (es) 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2007005466A MX2007005466A (es) 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii.
MX2014005051A MX350293B (es) 2004-11-12 2005-11-14 Modificacion dirigida al sitio del factor viii.

Country Status (32)

Country Link
US (4) US7632921B2 (en:Method)
EP (9) EP3243833B1 (en:Method)
JP (5) JP2008524117A (en:Method)
KR (7) KR20180110192A (en:Method)
CN (6) CN103102406B (en:Method)
AU (1) AU2005304622B2 (en:Method)
BE (1) BE2019C523I2 (en:Method)
BR (2) BR122016022033B8 (en:Method)
CA (1) CA2586379C (en:Method)
CY (3) CY1119292T1 (en:Method)
DK (3) DK2371856T3 (en:Method)
ES (4) ES2930143T3 (en:Method)
FR (1) FR19C1031I2 (en:Method)
HN (1) HN2007015683A (en:Method)
HR (2) HRP20180481B1 (en:Method)
HU (5) HUE059193T2 (en:Method)
IL (3) IL182903A (en:Method)
LT (5) LT2363414T (en:Method)
LU (1) LUC00118I2 (en:Method)
MA (1) MA29663B1 (en:Method)
MX (3) MX392760B (en:Method)
NL (1) NL300989I2 (en:Method)
NO (3) NO20210454A1 (en:Method)
NZ (1) NZ555032A (en:Method)
PH (2) PH12014500352B1 (en:Method)
PL (3) PL2363414T3 (en:Method)
PT (4) PT2371856T (en:Method)
RU (1) RU2423380C2 (en:Method)
SI (4) SI2363414T1 (en:Method)
UA (1) UA95225C2 (en:Method)
WO (1) WO2006053299A2 (en:Method)
ZA (1) ZA200703696B (en:Method)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06015234A (es) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
CN103102406B (zh) 2004-11-12 2015-05-27 拜尔健康护理有限责任公司 Fviii的位点定向修饰
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
CA2704234A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
KR101841870B1 (ko) * 2008-05-16 2018-03-23 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
PL2349342T3 (pl) * 2008-10-17 2019-01-31 Baxalta GmbH Zmodyfikowane czynniki krwi zawierające mały stopień polimeru rozpuszczalnego w wodzie
CA2740793A1 (en) * 2008-11-03 2010-06-03 Haiyan Jiang Method for the treatment of hemophilia
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
JP2012518029A (ja) * 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
PL2408800T3 (pl) * 2009-03-20 2016-11-30 Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
EP2470559B1 (en) * 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
ME02964B (me) 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
WO2011101242A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
SG183309A1 (en) * 2010-02-21 2012-09-27 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
WO2011130694A2 (en) 2010-04-15 2011-10-20 Oligasis High molecular weight zwitterion-containing polymers
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG10201509149VA (en) * 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
CN103269723B (zh) 2010-12-22 2017-04-05 百深有限责任公司 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
JP2014520094A (ja) * 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
ES2724778T3 (es) 2011-06-10 2019-09-16 Bioverativ Therapeutics Inc Compuestos procoagulantes y procedimientos de uso de los mismos
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN119192402A (zh) 2012-02-15 2024-12-27 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
DK2822577T3 (en) * 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
EP2666782A1 (en) 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
EA201890671A1 (ru) 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. Препараты полипептида фактора viii
CA2905739A1 (en) * 2013-03-15 2014-09-25 Bayer Healthcare Llc Recombinant factor viii formulations
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP3760639B1 (en) 2013-09-08 2025-10-22 Kodiak Sciences Inc. Zwitterionic polymers for use as conjugates with factor viii
AU2014339034A1 (en) * 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015107222A1 (en) 2014-01-20 2015-07-23 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
JP7058940B2 (ja) 2014-03-24 2022-04-25 バイオベラティブ セラピューティクス インコーポレイテッド 凍結乾燥第ｉｘ因子製剤
CA2944909A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
EP3129463B1 (en) 2014-04-10 2021-05-26 Bayer Healthcare LLC Compounded media powder formulation and method of preparation of liquid medium for cell culture
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
DK3297656T3 (da) 2015-05-22 2020-03-09 CSL Behring Lengnau AG Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
SG10201912498YA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated truncated von willebrand factor
CN108779165B (zh) 2016-01-07 2022-12-02 康诺贝林伦瑙有限公司 突变的冯·维勒布兰德因子
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
KR20190083355A (ko) 2016-11-16 2019-07-11 바이엘 헬쓰케어 엘엘씨 적혈구 표적화된 인자 viii 및 이를 사용하는 방법
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
BR112019011115A2 (pt) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc. métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
KR102575788B1 (ko) 2018-05-18 2023-09-08 정저우 젠사이언시스 인코포레이티드 개선된 fviii 융합 단백질 및 이의 용도
LT3793588T (lt) 2018-05-18 2025-06-25 Bioverativ Therapeutics Inc. Hemofilijos a gydymo būdai
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
CN114828870A (zh) * 2019-12-06 2022-07-29 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
MX9306133A (es) 1992-10-02 1994-04-29 Kabi Pharmacia Ab Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador.
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995011987A1 (en) 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
CN1081836C (zh) * 1995-06-21 2002-03-27 摩托罗拉公司 提供全向场型图的方法和天线
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
DE69736780T2 (de) * 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
NZ502375A (en) 1997-07-14 2001-11-30 Bolder Biotechnology Inc The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1023078A4 (en) * 1997-10-17 2004-09-29 Harvest Technologies Corp PRECIPITATION OF A FIBRINOGEN CONCENTRATE ENRICHED WITH A GROWTH FACTOR OBTAINED FROM A PLASMA ENRICHED PLASMA
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
DE69922189T2 (de) 1998-04-27 2005-11-10 Opperbas Holding B.V. Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
WO2002024723A1 (en) 2000-09-19 2002-03-28 Emory University Modified factor viii
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
HUP0401124A3 (en) * 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP4361786B2 (ja) 2001-06-14 2009-11-11 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
AU2002337901B2 (en) 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
JP2005538694A (ja) 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
JP4490369B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
MXPA05007348A (es) 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
CN1767857A (zh) * 2003-02-26 2006-05-03 尼克塔治疗亚拉巴马公司 聚合物－因子ⅷ部分共轭物
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
ATE478093T1 (de) 2003-05-12 2010-09-15 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
HUE043911T2 (hu) 2003-05-23 2019-09-30 Nektar Therapeutics Két PEG láncot tartalmazó PEG származékok
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (en) 2003-12-03 2010-04-07 University of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
CN103102406B (zh) 2004-11-12 2015-05-27 拜尔健康护理有限责任公司 Fviii的位点定向修饰
JP2008534559A (ja) 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
KR20070110260A (ko) 2007-11-16
LT1824988T (lt) 2017-10-25
JP2015134780A (ja) 2015-07-27
CY1123384T1 (el) 2021-12-31
NO20072997L (no) 2007-06-27
ZA200703696B (en) 2008-08-27
JP2017101028A (ja) 2017-06-08
HUS1900026I1 (hu) 2022-04-28
KR101483917B1 (ko) 2015-01-16
KR20180110192A (ko) 2018-10-08
JP2013067621A (ja) 2013-04-18
JP6018238B2 (ja) 2016-11-02
MX2007005466A (es) 2007-10-19
PT2371856T (pt) 2022-08-12
DK2371856T3 (en) 2022-08-08
LTPA2019509I1 (lt) 2019-08-26
IL232540A0 (en) 2014-06-30
MX350293B (es) 2017-09-04
RU2423380C2 (ru) 2011-07-10
WO2006053299A3 (en) 2006-08-24
PH12019501613A1 (en) 2020-09-14
EP2363414A3 (en) 2012-03-21
CY2019024I1 (el) 2019-11-27
BRPI0517795A8 (pt) 2018-12-26
EP3130601A1 (en) 2017-02-15
UA95225C2 (ru) 2011-07-25
NL300989I2 (nl) 2019-11-28
FR19C1031I1 (en:Method) 2019-06-28
NO344606B1 (no) 2020-02-10
LT2363414T (lt) 2022-10-25
CY2019024I2 (el) 2019-11-27
CN107082806A (zh) 2017-08-22
US20130274445A1 (en) 2013-10-17
KR20120136413A (ko) 2012-12-18
HK1117875A1 (en) 2009-01-23
EP1824988A2 (en) 2007-08-29
BR122016022033B8 (pt) 2021-05-25
KR20140019489A (ko) 2014-02-14
LUC00118I1 (en:Method) 2019-05-13
RU2007121517A (ru) 2008-12-20
KR20130036780A (ko) 2013-04-12
NZ555032A (en) 2010-02-26
US20160051633A1 (en) 2016-02-25
NO345800B1 (no) 2021-08-09
PT3130601T (pt) 2020-10-01
KR20140091618A (ko) 2014-07-21
CN105148287A (zh) 2015-12-16
LT3130601T (lt) 2020-09-10
ES2633916T3 (es) 2017-09-26
KR101468345B1 (ko) 2014-12-03
LUC00118I2 (en:Method) 2019-12-27
HK1218718A1 (zh) 2017-03-10
JP6487895B2 (ja) 2019-03-20
EP3323829B1 (en) 2020-07-15
EP2371856A3 (en) 2012-03-14
MA29663B1 (fr) 2008-08-01
BRPI0517795A (pt) 2008-10-21
EP3130601B1 (en) 2020-07-15
US20060115876A1 (en) 2006-06-01
PH12014500352A1 (en) 2015-07-20
US20100081615A1 (en) 2010-04-01
PL2363414T3 (pl) 2022-09-05
BE2019C523I2 (en:Method) 2025-02-10
EP3243834A1 (en) 2017-11-15
LTC1824988I2 (lt) 2021-02-25
BRPI0517795B1 (pt) 2020-03-31
IL182903A0 (en) 2007-08-19
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
WO2006053299A2 (en) 2006-05-18
HRP20070268B1 (hr) 2018-04-20
CA2586379A1 (en) 2006-05-18
PH12014500352B1 (en) 2019-09-25
SI1824988T1 (sl) 2017-11-30
CN105753968A (zh) 2016-07-13
PT1824988T (pt) 2017-07-21
NO20200044A1 (no) 2007-06-27
EP1824988A4 (en) 2008-12-31
HN2007015683A (es) 2011-07-11
EP3243833B1 (en) 2020-06-17
JP2017105773A (ja) 2017-06-15
EP2371856B1 (en) 2022-05-18
JP6109523B2 (ja) 2017-04-05
EP2371856A2 (en) 2011-10-05
EP2363414B1 (en) 2022-05-18
PL1824988T3 (pl) 2018-01-31
CA2586379C (en) 2012-04-03
HRP20070268A2 (en) 2007-09-30
HRP20180481A2 (hr) 2018-06-29
HRP20180481B1 (hr) 2022-02-18
AU2005304622B2 (en) 2012-03-29
CN101124331B (zh) 2013-04-24
EP2772500B1 (en) 2019-12-25
HUE033776T2 (en) 2018-01-29
AU2005304622A1 (en) 2006-05-18
PL2371856T3 (pl) 2022-08-22
BRPI0517795B8 (pt) 2021-05-25
DK1824988T3 (en) 2017-08-07
CN103102406A (zh) 2013-05-15
EP3153181A1 (en) 2017-04-12
US9364520B2 (en) 2016-06-14
ES2930159T3 (es) 2022-12-07
ES2821832T3 (es) 2021-04-27
HUE050542T2 (hu) 2020-12-28
IL232540A (en) 2017-08-31
EP3323829A1 (en) 2018-05-23
JP2008524117A (ja) 2008-07-10
BR122016022033B1 (pt) 2021-03-02
CY1119292T1 (el) 2018-02-14
IL234433B (en) 2019-11-28
DK2363414T3 (da) 2022-08-08
US7632921B2 (en) 2009-12-15
EP2772500A1 (en) 2014-09-03
HK1182121A1 (en) 2013-11-22
CN101124331A (zh) 2008-02-13
FR19C1031I2 (fr) 2020-06-05
CN103214569A (zh) 2013-07-24
CN105148287B (zh) 2019-07-09
ES2930143T3 (es) 2022-12-07
JP6559642B2 (ja) 2019-08-14
EP1824988B1 (en) 2017-04-19
HUE059193T2 (hu) 2022-10-28
KR101904630B1 (ko) 2018-10-04
PT2363414T (pt) 2022-08-04
KR101654011B1 (ko) 2016-09-05
EP2363414A2 (en) 2011-09-07
EP3243833A1 (en) 2017-11-15
NL300989I1 (nl) 2019-05-22
KR20160105928A (ko) 2016-09-07
SI2371856T1 (sl) 2022-09-30
CN103214569B (zh) 2016-12-28
HUE060016T2 (hu) 2023-01-28
CN103102406B (zh) 2015-05-27
IL182903A (en) 2014-09-30
KR101243564B1 (ko) 2013-03-27
LT2371856T (lt) 2022-08-25
SI3130601T1 (sl) 2020-11-30
US9096656B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
MX392760B (es) Modificacion dirigida al sitio del factor viii.
ECSP13012771A (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
ATE537844T1 (de) Dauerhafte lokalanästhetische zusammensetzung mit saib
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
EA201390600A1 (ru) Терапевтические наночастицы с сополимерами с большим молекулярным весом
CR10327A (es) "PIRIDIN(3-4-b) PIRAZINONAS"
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
DE602005018947D1 (de) Kombination von klebrigmacher und poly-alpha-olefin-öl
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
MX373193B (es) Conjugados de hemoglobina óxido de polialquileno valerato.
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
MX2017015375A (es) Variantes de oxintomodulina pegilada.
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
EP4448752A4 (en) Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures
DE602006020155D1 (de) Pharmazeutische wundheilungs-zusammensetzungen in ren und natriumhyaluronat
SV2007002756A (es) Modificacion dirigida al sitio del fviii
GT200700040A (es) Modificacion dirigida al sitio del fviii
MY151329A (en) Site-directed modification of fviii
MY173864A (en) Site-directed modification of fviii
MY181129A (en) Site-directed modification of fviii
AR058532A1 (es) Tratamientos de trastornos neurodegenerativos